T1	Participants 455 477	A total of 38 patients
T2	Participants 526 572	oral ganciclovir (1 g t.i.d., n=14, GAN group)
T3	Participants 576 624	oral valacyclovir (2 g q.i.d., n=12, VAL group).
T4	Participants 625 672	A third group (C, n=12) received no prophylaxis
T5	Participants 885 946	Thirty-six out of 38 (94.7%) recipients were CMV-seropositive
T6	Participants 993 1060	13 episodes of CMV disease in eight (66.7%) patients of the C group
T7	Participants 130 157	after renal transplantation
